ES2058537T3 - Procedimiento de resolucion de espiro-hidantoinas racemicas. - Google Patents

Procedimiento de resolucion de espiro-hidantoinas racemicas.

Info

Publication number
ES2058537T3
ES2058537T3 ES89307339T ES89307339T ES2058537T3 ES 2058537 T3 ES2058537 T3 ES 2058537T3 ES 89307339 T ES89307339 T ES 89307339T ES 89307339 T ES89307339 T ES 89307339T ES 2058537 T3 ES2058537 T3 ES 2058537T3
Authority
ES
Spain
Prior art keywords
spyro
ureid
racemic
hydantoine
diona
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89307339T
Other languages
English (en)
Inventor
Marcus Brackeen
Harry Ralph Howard Jr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PFIZER
Pfizer Inc
Original Assignee
PFIZER
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PFIZER, Pfizer Inc filed Critical PFIZER
Application granted granted Critical
Publication of ES2058537T3 publication Critical patent/ES2058537T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

SE DESCRIBE UN NUEVO PROCEDIMIENTO EN TRES ETAPAS PARA RESOLVER UN COMPUESTO DE ESPIRO-HIDANTOINA RACEMICO EN SUS ANTIPODAS OPTICOS, QUE INCLUYE (1) HACER REACCIONAR DICHO COMPUESTO RACEMICO CON UN ISOCIANATO ASIMETRICO OPTICAMENTE ACTIVO DE FORMULA RNCO, DONDE R ES (S)- O (R)-1-FENILETILO, O (S)- O (R)-1-(1-NAFTIL)ETILO, PARA FORMAR EL CORRESPONDIENTE COMPUESTO UREIDO DIASTEREOMERO; (2) SEPARAR LA MEZCLA DIASTEREOMERA RESULTANTE EN SUS PARTES COMPONENTES; Y (3) DESPUES CONVERTIR LOS DIASTEREOMEROS UREIDOS SEPARADOS, OBTENIDOS EN LA ETAPA (B) EN LOS CORRESPONDIENTES COMPUESTOS DE HIDANTOINA ASIMETRICOS, POR TRATAMIENTO CON UN ALCOXIDO INFERIOR C1-C4 DE METAL ALCALINO, SEGUIDO POR ACIDIFICACION, CON LO QUE SE OBTIENE EL ISOMERO OPTICO DESEADO. LOS PRODUCTOS FINALES ASI OBTENIDOS, TALES COMO (4S)-(+)-6-FLUOR-2,3-DIHIDRO-ESPIRO [4H-1-BENZOPIRAN 4,4''-IMIDAZOLIDIN]-2'',5''-DIONA (SORBINIL) Y (5''S)-3''-CLORO-5'',6'',7'',8''TATRAHIDRO-ESPIRO [IMIDAZOLIDIN-4,5''-QUINOLIDIN]-2,5-DIONA, SE SABE QUE SON UTILES PARA PREVENIR O ALIVIAR CIERTAS COMPLICACIONES DIABETICAS CRONICAS. LOS INTERMEDIOS UREIDO DIASTEROISOMEROS ANTES MENCIONADOS SON COMPUESTOS NUEVOS.
ES89307339T 1988-07-27 1989-07-19 Procedimiento de resolucion de espiro-hidantoinas racemicas. Expired - Lifetime ES2058537T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/224,966 US4952694A (en) 1988-07-27 1988-07-27 Novel resolution process for racemic spiro-hydantoins

Publications (1)

Publication Number Publication Date
ES2058537T3 true ES2058537T3 (es) 1994-11-01

Family

ID=22842974

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89307339T Expired - Lifetime ES2058537T3 (es) 1988-07-27 1989-07-19 Procedimiento de resolucion de espiro-hidantoinas racemicas.

Country Status (24)

Country Link
US (1) US4952694A (es)
EP (1) EP0352959B1 (es)
JP (1) JPH0625152B2 (es)
KR (1) KR910002839B1 (es)
CN (1) CN1023645C (es)
AT (1) ATE93859T1 (es)
DD (1) DD284020A5 (es)
DE (1) DE68908812T2 (es)
DK (1) DK169033B1 (es)
EG (1) EG18934A (es)
ES (1) ES2058537T3 (es)
FI (1) FI893576L (es)
HU (1) HU204527B (es)
IE (1) IE892420L (es)
IL (1) IL91055A0 (es)
MX (1) MX173143B (es)
MY (1) MY104136A (es)
NO (1) NO168773C (es)
NZ (1) NZ230091A (es)
PL (1) PL161181B1 (es)
PT (1) PT91273A (es)
RU (1) RU1777599C (es)
YU (1) YU47209B (es)
ZA (1) ZA895680B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5151544A (en) * 1990-05-25 1992-09-29 Alcon Laboratories, Inc. Intermediates in the preparation of chiral spirofluorenehydantoins
US5206367A (en) * 1992-02-18 1993-04-27 Pfizer Inc. Preparation of optically active spiro-hydantoins
US5811605A (en) * 1997-02-19 1998-09-22 Ppg Industries, Inc. Preparation of 1,2,3,3-tetrachloropropene
WO2009011261A1 (ja) 2007-07-19 2009-01-22 Tokuyama Corporation ヒダントイン環を有する化合物及びその製造方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4117230A (en) * 1976-10-18 1978-09-26 Pfizer Inc. Hydantoin derivatives as therapeutic agents
US4130714A (en) * 1977-05-23 1978-12-19 Pfizer Inc. Hydantoin therapeutic agents
US4248882A (en) * 1980-02-12 1981-02-03 Pfizer Inc. Treating diabetes-associated complications with hydantoin amines
ATE23046T1 (de) * 1982-11-10 1986-11-15 Pfizer Sorbinil durch optische aufspaltung mit aminopinanderivaten.
EP0172719B1 (en) * 1984-08-20 1988-09-21 Pfizer Inc. Process for the production as asymmetric hydantoins
WO1986002647A1 (en) * 1984-10-30 1986-05-09 Pfizer Inc. Spiro-heteroazolones for treatment of diabetes complications

Also Published As

Publication number Publication date
IE892420L (en) 1990-01-27
FI893576A0 (fi) 1989-07-26
YU47209B (sh) 1995-01-31
FI893576A7 (fi) 1990-01-28
FI893576L (fi) 1990-01-28
ATE93859T1 (de) 1993-09-15
RU1777599C (ru) 1992-11-23
EG18934A (en) 1994-03-30
NO168773C (no) 1992-04-01
DK367889D0 (da) 1989-07-26
KR910002862A (ko) 1991-02-26
PL161181B1 (pl) 1993-05-31
NO168773B (no) 1991-12-23
DE68908812D1 (de) 1993-10-07
ZA895680B (en) 1991-03-27
PT91273A (pt) 1990-02-08
MX173143B (es) 1994-02-02
IL91055A0 (en) 1990-02-09
EP0352959A1 (en) 1990-01-31
JPH0288576A (ja) 1990-03-28
DD284020A5 (de) 1990-10-31
DK169033B1 (da) 1994-08-01
YU149189A (en) 1991-02-28
HUT56369A (en) 1991-08-28
AU603301B2 (en) 1990-11-08
AU3898889A (en) 1990-02-01
US4952694A (en) 1990-08-28
MY104136A (en) 1994-02-28
EP0352959B1 (en) 1993-09-01
DK367889A (da) 1990-01-29
HU204527B (en) 1992-01-28
CN1040199A (zh) 1990-03-07
JPH0625152B2 (ja) 1994-04-06
KR910002839B1 (ko) 1991-05-06
NO893053D0 (no) 1989-07-26
MX16955A (es) 1993-06-01
NO893053L (no) 1990-01-29
DE68908812T2 (de) 1993-12-09
NZ230091A (en) 1991-01-29
CN1023645C (zh) 1994-02-02

Similar Documents

Publication Publication Date Title
Boyce et al. Total synthesis of thiangazole, a novel inhibitor of HIV-1 from polyangium sp
ES2126697T3 (es) Inhibidores de enzimas de conversion de angiotensina que contienen lactamas de anillos multiples.
AR016523A1 (es) Compuestos de indol como agentes anti-inflamatorios/analgesicos, composiciones farmaceuticas que los contienen y procedimiento de tratamiento
BR9813566A (pt) Composição biocida estabilizada contendo compostos de halopropinila
MX9402950A (es) Piridil-3-carbinoles 4-substituidos herbicidas.
RU2015978C1 (ru) N-замещенные производные (3r, 4r)-3-этил-4-[(1-метил-1h-имидазол-5-ил)-метил]-2-пирролидона или их фармацевтически приемлемые кислотно-аддитивные соли, обладающие антиглаукомным действием
ES2058537T3 (es) Procedimiento de resolucion de espiro-hidantoinas racemicas.
AR006058A1 (es) Procedimientos para preparar compuestos de dicianoacetato y de 1,2-pirazol-5-amino-3-substituido
PE120899A1 (es) Derivados de d-homo-9,10-seco-colesta-23-in-3,25-diol
WO1998021213A3 (en) 2R,4S,R,S- and 2S,4R,R,S-hydroxyitraconazole- and hydroxysaperconazole derivatives
ES2128959A1 (es) Procedimiento de separacion de carbinoles.
AU6117598A (en) Compounds
MX9803966A (es) 25-hidroxi-16-en-26,27-bishomo-colecalciferoles.
AU7591187A (en) Novel fungicidal compositions
PE20030764A1 (es) Derivados de d-prolina
ES2093040T3 (es) Hidroximetil-indolizidinas y quinolizidinas.
DK0520372T3 (da) Inositol-phosphat-analoger som calciumantagonistiske stoffer
WO2000075116A3 (en) Tricyclic analgesics
ES2126923T3 (es) 8-fluoro-antraciclinas, procedimientos para su preparacion y composiciones farmaceuticas que las contienen.
EP0046679A3 (en) Total synthesis of 1rs,4sr,5rs-4-(4,8-dimethyl-5-hydroxy-7-nonen-1-yl)-4-methyl-3,8-dioxabicyclo(3.2.1)octane-1-acetic acid
ES540841A0 (es) Un procedimiento compuesto de espiro 2h-1,4-benzodioxepin-3 (5h)4'-piperidina y -3'-pirrolidina
NZ234811A (en) Specific isomer of a benzopyran derivative and pharmaceutical compositions thereof
PT878195E (pt) Utilizacao de um composto 2-aroil-3-arilbenzo(b)tiofeno para a reducao de fibrinogenio
ES514117A0 (es) "procedimiento para la preparacion de l-prolina".
EP0045631A3 (en) Synthesis of dioxabicyclo(3.2.1)octanes and oxepanes

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 352959

Country of ref document: ES